

Daily evidence digest

21 June 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Mucormycosis, smoking and COVID-19 outcomes, ATAGI revised recommendations on AstraZeneca vaccine

Peer reviewed journals featured:

- A systematic review on COVID-19-associated mucormycosis [here](#)
- Observational studies on:
 - The impact of smoking on COVID-19 outcomes [here](#)
 - Convalescent plasma therapy for COVID-19 patients with haematologic cancers [here](#) and associated commentary [here](#)
 - Persistent symptoms and lab abnormalities in recovered patients from COVID-19 [here](#)
- Machine learning-based mortality risk prediction for hospitalised COVID-19 patients [here](#)
- An editorial on COVID-19 failures of national and global leadership in the US and the UK [here](#)
- Commentary on preparing for the next COVID-19 wave in Canada [here](#)

Letters and correspondence discussed:

- Characterising post-acute COVID-19 syndrome [here](#)

Guidance and reports

- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The TGA released its COVID-19 vaccine weekly safety report [here](#)
- ATAGI released revised recommendations on the use of AstraZeneca vaccine [here](#)

News and blogs

- Vaccination to become mandatory for care home staff and could extend to NHS in England [here](#)
- Regeneron's antibody combination cuts deaths in seronegative patients [here](#)
- Exponential growth in infections in England is driven by young people [here](#)
- Lung transplants for COVID-19 [here](#)

[Click here](#) to subscribe to the daily evidence digest.